Apellis Pharmaceuticals Incの将来のP / E
Apellis Pharmaceuticals Incの将来のP / Eは何ですか。
Apellis Pharmaceuticals Incの将来のP / Eは-11.54です。
将来のP / Eの定義は何ですか。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
NASDAQのセクタHealth Careにおける将来のP / Eの企業と比べるApellis Pharmaceuticals Inc
Apellis Pharmaceuticals Incは何をしますか。
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Incと類似の将来のp / e
- Biostageの将来のP / Eは-12.00です。
- Immunovant Incの将来のP / Eは-11.92です。
- U.S. Xpress Enterprises Incの将来のP / Eは-11.88です。
- CollPlant Biotechnologies Ltdの将来のP / Eは-11.63です。
- Oncocyteの将来のP / Eは-11.63です。
- Parrot SAの将来のP / Eは-11.57です。
- Apellis Pharmaceuticals Incの将来のP / Eは-11.54です。
- Biostageの将来のP / Eは-11.43です。
- Soligenix Incの将来のP / Eは-11.34です。
- Abivax SAの将来のP / Eは-11.32です。
- GrowGeneration Corpの将来のP / Eは-11.31です。
- Obalon Therapeutics Incの将来のP / Eは-11.30です。
- Cassava Sciences Incの将来のP / Eは-11.29です。